
Episode 24. ASCO/EHA 2023 Special: Updates on CAR T-cell Therapy in Myeloma
Blood Cancer Talks
00:00
The Importance of Comparative Efficacy in Early Relapse Patients
The real world data, I think, can also help us in this regard. Would you reserve CAR-T only for high-risk patients or those with aggressive relapse? It's a great question and one that I probably am still working through myself. And then once we get more survival data and more data on these non-relaps mortality, second malignancies, et cetera, if we're more comfortable that that's not eating in too much to the survival picture, there will be going to be using it for a lot more patients.
Transcript
Play full episode